<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">The median follow-up time of surviving patients was 54.5 months (range, 3–75 months). The ICT/CCRT arm had a 5-year OS rate of 47%, compared with 52% in the CCRT arm (
 <italic>p</italic> = 0.450). Furthermore, PFS was 29% and 45% (
 <italic>p</italic> = 0.035), LRC was 35% and 56% (
 <italic>p</italic> = 0.026), and DM was 28% and 18% (
 <italic>p</italic> = 0.69) at 5 years in the ICT/CCRT and CCRT arms, respectively (
 <xref rid="fig2" ref-type="fig">Fig. 2</xref>). The second primary malignancy rate was 10% and 16% in the ICT/CCRT and CCRT arms, respectively (
 <italic>p</italic> = 0.203). Disease failure occurred in 83 patients (54.9%), namely 51 (66.2%) in the ICT/CCRT arm and 32 (43.3%) in the CCRT arm. The rates of the first failure event being at locoregional, distant, or locoregional and distant sites were 50.6%, 3.9%, and 11.7%, respectively, in the ICT/CCRT arm and 28.4%, 2.7%, and 12.2% in the CCRT arm. Salvage surgery for residual or relapsed disease was performed in 12 (15.6%) ICT/CCRT patients and 6 (8.1%) CCRT patients (
 <italic>p</italic> = 0.370).
</p>
